Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Access barriers and treatment patterns in Philadelphia-negative myeloproliferative neoplasms (Ph- MPN): Insights from a brazilian physician survey

View Full Paper
Ask AI
Bookmark
Share

Authors

RDRuddy DalfeorMGMariana Guaraná

Discussion

Loading...

Member takes

Overview

Survey reveals gaps in diagnosis and treatment access for Ph-MPNs among Brazilian hematologists, highlighting challenges.

Key Points

  • Significant treatment access disparities exist for patients with polycythemia vera and myelofibrosis in Brazil.
  • About 60% of hematologists reported limited access to next-generation sequencing, affecting patient management.
  • Assessment using a national survey among Brazilian hematologists evaluated diagnostic and treatment challenges in managing Ph-MPNs.
  • These findings underscore the need for better access to diagnostics and therapies for patients with Philadelphia-negative myeloproliferative neoplasms.

Cite This Study

Dalfeor et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6bfhttps://doi.org/10.1182/blood-2025-7356
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Diagnostic conformity to who criteria and use of cytoreductive therapy in classical myeloproliferative neoplasms: Experience from a resource-limited country2025
  2. 2Global assessment of patient and caregiver unmet needs in myeloproliferative neoplasms (MPNs): Findings from the 2024 international assessment2025
  3. 3Myeloproliferative neoplasms in Mexico: An analysis of clinical features, driver mutations, and disease progression patterns in a case series.2025
  4. 4Clinicopathological characteristics and outcome of patients with Philadelphia negative myeloproliferative neoplasms: first report from Upper Egypt2025
  5. 5Patient and clinician perspectives on the diagnosis and management of polycythemia vera: Results from concurrent surveys2025